Back to News & Stories
PxWire Volume 15, Issue No. 2
Check out the latest issue of PxWire here! And see key highlights below:
- PEPFAR documented 2.5 million new PrEP users in 2024,who could now lose access to PEPFAR-supported PrEP services.
- Modelling data from South Africa demonstrate the potential of injectable PrEP to dramatically reduce HIV incidence by up to 90% by 2044, and potentially even sooner with more aggressive uptake.
- The HIV prevention market is headed toward a period of significant opportunity—and possible congestion—as a slate of new products are on track for continued development and potential introduction to the market in 2027 and 2028.